Drugs / UB-221
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04175704 | Dec 2023 → Nov 2024 | chronic idiopathic urticaria | United BioPharma | Unknown | No outcome recorded |
| Phase 1 | NCT04404023 | Dec 2023 → Jun 2024 | chronic idiopathic urticaria | UBP Greater China (Shanghai) Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03632291 | Apr 2019 → Jan 2021 | chronic urticaria | United BioPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05298215 | Oct 2022 → Dec 2023 | chronic urticaria | United BioPharma | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175704 ↗ |
| Action | Inhibit | “The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking” NCT05298215 ↗ |
| Modality | Monoclonal antibody | “Active ingredient: Anti-IgE monoclonal antibody” NCT04175704 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT03632291 ↗ |